You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriprolidine
Accession NumberDB00427  (APRD00306)
TypeSmall Molecule
GroupsApproved
DescriptionFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. [PubChem]
Structure
Thumb
Synonyms
Actahist
Actidil
Actifed
Allerfed
Corphed
Histafed
Myfed
Myidyl
Trilitron
Triphed
Tripolidina
Triprolidin
Triprolidine
Triprolidinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Histexsyrup2.5 mg/5mLoralAllegis Pharmaceuticals, LLC2014-03-04Not applicableUs
Histex Pd Dropssyrup.938 mg/mLoralAllegis Pharmaceuticals, LLC2014-03-06Not applicableUs
Vanahist Pdliquid.625 mg/mLoralGm Pharmaceuticals,Inc2014-03-19Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AnminAND
VenenSato Seiyaku
Brand mixtures
NameLabellerIngredients
Actifed DM SyrupGlaxo Wellcome Inc.
Actifed DM TabletsGlaxo Wellcome Inc.
Actifed Plus CapletGlaxo Wellcome Inc.
Actifed Plus CapletsMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Actifed SyrupGlaxo Wellcome Inc.
Actifed TabletsGlaxo Wellcome Inc.
AprodineRebel Distributors Corp
CoactifedGlaxosmithkline Inc
CotrifedTechnilab Pharma Inc.
Covan SyrupPharmascience Inc
Ed-A-hist PseEDWARDS PHARMACEUTICALS, INC.
Histex AcAllegis Pharmaceuticals, LLC
Histex-DMAllegis Pharmaceuticals, LLC
Histex-PEAllegis Pharmaceuticals, LLC
Poly Hist NcPoly Pharmaceuticals, Inc.
Ratio-cotridinTeva Canada Limited
Ratio-cotridin ExpectorantTeva Canada Limited
SilafedSilarx Pharmaceuticals, Inc
Triacin-CSTI Pharma LLC
Triprofed TabIcn Canada Ltd.
Wal-actWALGREEN CO.
Salts
Name/CASStructureProperties
Triprolidine Hydrochloride
Thumb
  • InChI Key: WYUYEJNGHIOFOC-NWBUNABESA-N
  • Monoisotopic Mass: 314.154976453
  • Average Mass: 314.852
DBSALT000623
Categories
UNII2L8T9S52QM
CAS number486-12-4
WeightAverage: 278.3914
Monoisotopic: 278.178298714
Chemical FormulaC19H22N2
InChI KeyInChIKey=CBEQULMOCCWAQT-WOJGMQOQSA-N
InChI
InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
IUPAC Name
2-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridine
SMILES
CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropenes. These are compounds containing a phenylpropene moiety, which consists of a propene substituent bound to a phenyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropenes
Direct ParentPhenylpropenes
Alternative Parents
Substituents
  • Phenylpropene
  • Styrene
  • Toluene
  • N-alkylpyrrolidine
  • Pyridine
  • Heteroaromatic compound
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis; allergic conjunctivitis; and mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold.
PharmacodynamicsIn allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Triprolidine, is a histamine H1 antagonist that competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Triprolidine has anticholinergic and sedative effects.
Mechanism of actionTriprolidine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Related Articles
AbsorptionRapidly absorbed in the intestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life4 to 6 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, weakness, inco-ordination, difficulty with micturition, respiratory depression, hypotension, agitation, irritability, convulsions, hypertension, palpitation and tachycardia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9905
Blood Brain Barrier+0.9664
Caco-2 permeable-0.5814
P-glycoprotein substrateSubstrate0.6644
P-glycoprotein inhibitor IInhibitor0.8311
P-glycoprotein inhibitor IINon-inhibitor0.6624
Renal organic cation transporterInhibitor0.8612
CYP450 2C9 substrateNon-substrate0.8143
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6075
CYP450 1A2 substrateNon-inhibitor0.8613
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8598
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9833
Rat acute toxicity2.7123 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7001
hERG inhibition (predictor II)Non-inhibitor0.5557
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Usl pharma inc
  • Alpharma us pharmaceuticals division
  • Halsey drug co inc
  • Pharmaceutical assoc inc div beach products
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tablet, coatedoral
Syruporal2.5 mg/5mL
Syruporal
Syruporal.938 mg/mL
Liquidoral
Liquidoral.625 mg/mL
Tablet, film coatedoral
Prices
Unit descriptionCostUnit
Triprolidine hcl crystals40.33USD g
Triprolidine 1.25 mg/5 ml liq0.15USD ml
Tripohist 1.25 mg/5 ml liquid0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point60 °CPhysProp
water solubility74.9 mg/LNot Available
logP3.92HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0537 mg/mLALOGPS
logP4.14ALOGPS
logP4.05ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)8.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.53 m3·mol-1ChemAxon
Polarizability33.09 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44. [PubMed:2568212 ]
  2. Simons FE: H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 1994 May;10(5):350-80. [PubMed:7913608 ]
  3. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055 ]
  4. Telekes A, Holland RL, Withington DA, Peck AW: Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers. Br J Clin Pharmacol. 1987 Jul;24(1):43-50. [PubMed:3620284 ]
External Links
ATC CodesR06AX07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Triprolidine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Triprolidine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Triprolidine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Triprolidine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Triprolidine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Triprolidine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Triprolidine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Triprolidine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triprolidine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Triprolidine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triprolidine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Triprolidine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Triprolidine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Triprolidine.
AmoxapineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Triprolidine.
AmphetamineAmphetamine may decrease the sedative activities of Triprolidine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Triprolidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triprolidine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Triprolidine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Triprolidine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Triprolidine.
AzelastineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triprolidine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Triprolidine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Triprolidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Triprolidine.
BenzphetamineBenzphetamine may decrease the sedative activities of Triprolidine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Triprolidine.
Benzylpenicilloyl PolylysineTriprolidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Triprolidine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
BrimonidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triprolidine.
BrompheniramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Triprolidine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triprolidine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triprolidine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triprolidine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triprolidine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Triprolidine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Triprolidine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Triprolidine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Triprolidine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triprolidine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triprolidine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Triprolidine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Triprolidine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Triprolidine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Triprolidine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triprolidine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Triprolidine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Triprolidine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Triprolidine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triprolidine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Triprolidine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Triprolidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triprolidine.
CitalopramThe risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Triprolidine.
ClidiniumThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Triprolidine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Triprolidine.
ClomipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triprolidine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triprolidine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Triprolidine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triprolidine.
CyclizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.
CyproheptadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triprolidine.
DapoxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Triprolidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Triprolidine.
DesipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Triprolidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triprolidine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Triprolidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triprolidine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triprolidine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Triprolidine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triprolidine.
DifenoxinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triprolidine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triprolidine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triprolidine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triprolidine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triprolidine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Triprolidine.
DoxepinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
DoxylamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Triprolidine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Triprolidine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Triprolidine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Triprolidine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Triprolidine.
EfavirenzThe risk or severity of adverse effects can be increased when Triprolidine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triprolidine.
EntacaponeThe risk or severity of adverse effects can be increased when Triprolidine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Triprolidine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triprolidine.
EthanolTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Triprolidine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine.
EthosuximideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Triprolidine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Triprolidine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triprolidine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Triprolidine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Triprolidine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Triprolidine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triprolidine.
EtoperidoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triprolidine.
EzogabineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Triprolidine.
FenfluramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triprolidine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Triprolidine.
FexofenadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Triprolidine.
FlunarizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Triprolidine.
FluoxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triprolidine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triprolidine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triprolidine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Triprolidine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Triprolidine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triprolidine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Triprolidine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Triprolidine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Triprolidine.
GuanfacineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Triprolidine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triprolidine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Triprolidine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Triprolidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Triprolidine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triprolidine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triprolidine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Triprolidine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
HydroxyzineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Triprolidine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triprolidine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Triprolidine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triprolidine.
LamotrigineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Triprolidine.
LevocabastineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triprolidine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triprolidine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triprolidine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Triprolidine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Triprolidine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Triprolidine.
LoratadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triprolidine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triprolidine.
Lu AA21004The risk or severity of adverse effects can be increased when Triprolidine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Triprolidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Triprolidine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Triprolidine.
MephentermineMephentermine may decrease the sedative activities of Triprolidine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Triprolidine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Triprolidine.
MetaxaloneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triprolidine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triprolidine.
MethamphetamineMethamphetamine may decrease the sedative activities of Triprolidine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Triprolidine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Triprolidine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triprolidine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triprolidine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Triprolidine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Triprolidine.
MethsuximideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triprolidine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Triprolidine.
MetyrosineTriprolidine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine.
MilnacipranThe risk or severity of adverse effects can be increased when Triprolidine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
MirtazapineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Triprolidine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Triprolidine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triprolidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
NabiloneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triprolidine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Triprolidine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Triprolidine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Triprolidine.
NortriptylineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Triprolidine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Triprolidine.
OrphenadrineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Triprolidine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Triprolidine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triprolidine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triprolidine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Triprolidine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triprolidine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triprolidine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triprolidine.
ParaldehydeTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Triprolidine.
ParoxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triprolidine.
PerampanelThe risk or severity of adverse effects can be increased when Triprolidine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Triprolidine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triprolidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triprolidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triprolidine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Triprolidine.
PhenterminePhentermine may decrease the sedative activities of Triprolidine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triprolidine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Triprolidine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Triprolidine.
PipotiazineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.
PramipexoleTriprolidine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Triprolidine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Triprolidine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triprolidine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Triprolidine.
PrimidoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Triprolidine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triprolidine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triprolidine.
PromethazineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Triprolidine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Triprolidine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Triprolidine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Triprolidine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Triprolidine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triprolidine.
RamelteonThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triprolidine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triprolidine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triprolidine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Triprolidine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Triprolidine.
RopiniroleTriprolidine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triprolidine.
RotigotineTriprolidine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triprolidine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Triprolidine.
ScopolamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triprolidine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Triprolidine.
SertralineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Triprolidine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Triprolidine.
StiripentolThe risk or severity of adverse effects can be increased when Triprolidine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triprolidine.
SuvorexantThe risk or severity of adverse effects can be increased when Triprolidine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triprolidine.
TetrabenazineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Triprolidine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Triprolidine.
ThalidomideTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Triprolidine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Triprolidine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Triprolidine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Triprolidine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triprolidine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triprolidine.
TiagabineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Triprolidine.
TizanidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triprolidine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Triprolidine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triprolidine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Triprolidine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triprolidine.
TrazodoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Triprolidine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triprolidine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triprolidine.
TrimipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trimipramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triprolidine.
VigabatrinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Triprolidine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Triprolidine.
ZiconotideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triprolidine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Triprolidine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Triprolidine.
ZonisamideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Triprolidine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Triprolidine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triprolidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Peroutka SJ, Snyder SH: Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain. Brain Res. 1981 Mar 16;208(2):339-47. [PubMed:7214150 ]
  2. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. [PubMed:3011460 ]
  3. Kuzmin AI, Zaretsky DV, Kalenikova EI, Zaretskaja MV, Medvedev OS, Chazov EI: The effect of histamine receptor antagonists on stress-induced catecholamine secretion: an adrenomedullary microdialysis study in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):311-6. [PubMed:10493107 ]
  4. Ziganshina LE, Ziganshin AU, Hoyle CH, Burnstock G: Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved. Inflamm Res. 1996 Feb;45(2):96-102. [PubMed:8907591 ]
  5. Hiroi T, Ohishi N, Imaoka S, Yabusaki Y, Fukui H, Funae Y: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther. 1995 Feb;272(2):939-44. [PubMed:7853212 ]
  6. Estelle F, Simons R: H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999 Nov;83(5):481-8. [PubMed:10582735 ]
  7. Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44. [PubMed:2568212 ]
  8. Simons FE: H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 1994 May;10(5):350-80. [PubMed:7913608 ]
  9. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055 ]
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23